Skip to main content

Newsroom

Press Releases

February 23, 2017
GAITHERSBURG, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2016. 2016 FINANCIAL HIGHLIGHTS (1) (2) (in millions) 4Q 2016 CY 2016     Combined & Contin...

 


Corporate Headquarters Ribbon Cutting

Featured Stories

BETHESDA, MD - The International Biomedical Research Alliance today announced…

MORE

Soligenix, Inc. Announced today that it has extended its development agreement with Emergent…

MORE

Emergent BioSolutions, a Gaithersburg-based drug developer, has signed a contract with the…

MORE

Featured Stories

BETHESDA, MD - The International Biomedical Research Alliance today announced…

MORE

Soligenix, Inc. Announced today that it has extended its development agreement with Emergent…

MORE

Emergent BioSolutions, a Gaithersburg-based drug developer, has signed a contract with the…

MORE

Media
Tracey Schmitt Lintott
schmittt@ebsi.com 
TEL 240-631-3394 

Investors
Robert Burrows 
burrowsr@ebsi.com 
TEL 240-631-3280